
Centessa (CNTA) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
15.0M
Operating Income
-30.8M
-205.18%
Net Income
-26.1M
-174.23%
EPS (Diluted)
$-0.20
Balance Sheet Metrics
Total Assets
527.8M
Total Liabilities
141.6M
Shareholders Equity
386.2M
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
-22.9M
Free Cash Flow
-57.2M
Revenue & Profitability Trend
Centessa Income Statement From 2019 to 2024
Metric | 2024 | 2023 | 2022 | 2020 | 2019 |
---|---|---|---|---|---|
Revenue | 0 | 6.9M | 0 | 0 | 0 |
Cost of Goods Sold | - | - | - | - | - |
Gross Profit | - | - | - | - | - |
Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Operating Expenses | |||||
Research & Development | 150.2M | 124.4M | 155.1M | 9.3M | 4.3M |
Selling, General & Administrative | 50.8M | 53.7M | 55.2M | 1.1M | 790.0K |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 201.1M | 178.1M | 210.3M | 10.4M | 5.1M |
Operating Income | -201.1M | -171.3M | -210.3M | -10.4M | -5.1M |
Operating Margin % | 0.0% | -2,499.4% | 0.0% | 0.0% | 0.0% |
Non-Operating Items | |||||
Interest Income | 14.0M | 10.5M | 244.0K | - | 5.0K |
Interest Expense | 10.1M | 9.9M | 7.3M | 378.0K | 118.0K |
Other Non-Operating Income | -35.8M | -5.4M | 362.0K | 155.0K | 105.0K |
Pre-tax Income | -232.9M | -176.1M | -217.0M | -10.7M | -5.1M |
Income Tax | 2.8M | -25.1M | -747.0K | - | - |
Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Net Income | -235.8M | -151.1M | -216.2M | -10.7M | -5.1M |
Net Margin % | 0.0% | -2,204.7% | 0.0% | 0.0% | 0.0% |
Key Metrics | |||||
EBITDA | -187.8M | -165.4M | -207.6M | -10.3M | -4.9M |
EPS (Basic) | $-2.06 | $-1.57 | $-2.31 | $-0.15 | $-0.07 |
EPS (Diluted) | $-2.06 | $-1.57 | $-2.31 | $-0.15 | $-0.07 |
Basic Shares Outstanding | 114473449 | 96177578 | 93400513 | 70890985 | 70890985 |
Diluted Shares Outstanding | 114473449 | 96177578 | 93400513 | 70890985 | 70890985 |
Income Statement Trend
Centessa Balance Sheet From 2020 to 2024
Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 383.2M | 128.0M | 393.6M | 595.1M | 7.2M |
Short-term Investments | 99.0M | 128.5M | 0 | - | - |
Accounts Receivable | - | - | - | - | - |
Inventory | - | - | - | - | - |
Other Current Assets | 1.8M | 1.6M | 3.3M | 993.0K | 6.0K |
Total Current Assets | 536.4M | 315.1M | 437.7M | 628.8M | 11.2M |
Non-Current Assets | |||||
Property, Plant & Equipment | 0 | 0 | - | - | - |
Goodwill | - | - | - | - | - |
Intangible Assets | - | - | - | - | - |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 28.6M | 32.2M | 5.4M | 699.0K | 552.0K |
Total Non-Current Assets | 40.4M | 45.2M | 6.6M | 861.0K | 552.0K |
Total Assets | 576.8M | 360.2M | 444.3M | 629.6M | 11.7M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 7.1M | 11.8M | 13.8M | 8.1M | 1.0M |
Short-term Debt | - | - | - | - | 5.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 710.0K | 839.0K | 690.0K | 102.0K | 922.0K |
Total Current Liabilities | 58.0M | 39.4M | 38.3M | 24.6M | 8.6M |
Non-Current Liabilities | |||||
Long-term Debt | 117.2M | 84.6M | 69.8M | 75.7M | - |
Deferred Tax Liabilities | - | - | - | - | - |
Other Non-Current Liabilities | 29.0K | 29.0K | - | 37.7M | - |
Total Non-Current Liabilities | 117.3M | 84.6M | 69.8M | 113.4M | 25.5M |
Total Liabilities | 175.3M | 124.0M | 108.1M | 138.1M | 34.1M |
Equity | |||||
Common Stock | 359.0K | 273.0K | 265.0K | 252.0K | 0 |
Retained Earnings | -988.7M | -752.9M | -601.9M | -385.7M | -22.4M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 401.5M | 236.2M | 336.2M | 491.6M | -22.4M |
Key Metrics | |||||
Total Debt | 117.2M | 84.6M | 69.8M | 75.7M | 5.6M |
Working Capital | 478.4M | 275.7M | 399.4M | 604.1M | 2.5M |
Balance Sheet Composition
Centessa Cash Flow Statement From 2019 to 2024
Metric | 2024 | 2023 | 2022 | 2020 | 2019 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | -235.8M | -151.1M | -216.2M | -10.7M | -5.1M |
Depreciation & Amortization | 942.0K | 810.0K | 131.0K | 0 | 6.0K |
Stock-Based Compensation | 33.5M | 29.4M | 25.0M | 336.0K | 236.0K |
Working Capital Changes | -10.9M | -16.7M | -5.4M | -1.4M | 268.0K |
Operating Cash Flow | -209.4M | -164.1M | -199.2M | -11.8M | -4.6M |
Investing Activities | |||||
Capital Expenditures | -34.0K | -169.0K | -1.1M | 0 | 0 |
Acquisitions | - | - | 0 | 0 | 0 |
Investment Purchases | -140.5M | -264.9M | 0 | - | - |
Investment Sales | 171.8M | 138.1M | 0 | - | - |
Investing Cash Flow | 31.3M | -127.0M | -931.0K | 0 | 0 |
Financing Activities | |||||
Share Repurchases | - | - | - | 0 | 0 |
Dividends Paid | - | - | - | - | - |
Debt Issuance | 109.3M | - | 0 | 1.4M | 3.8M |
Debt Repayment | -110.1M | - | - | 0 | 0 |
Financing Cash Flow | 353.5M | 20.8M | -261.0K | 1.4M | 9.0M |
Free Cash Flow | -142.1M | -160.5M | -201.7M | -10.6M | -5.8M |
Net Change in Cash | 175.4M | -270.3M | -200.3M | -10.4M | 4.5M |
Cash Flow Trend
Centessa Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-7.63
Forward P/E
-9.43
Price to Book
6.26
Price to Sales
144.08
PEG Ratio
1.53
Profitability Ratios
Profit Margin
0.00%
Operating Margin
-1,376.10%
Return on Equity
-72.92%
Return on Assets
-28.96%
Financial Health
Current Ratio
10.12
Debt to Equity
34.25
Beta
1.48
Per Share Data
EPS (TTM)
$-1.85
Book Value per Share
$2.58
Revenue per Share
$0.12
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
cnta | 2.1B | -7.63 | 6.26 | -72.92% | 0.00% | 34.25 |
Vertex | 101.6B | 28.19 | 5.91 | 22.77% | 31.86% | 8.89 |
Regeneron | 60.8B | 14.45 | 1.99 | 15.34% | 31.37% | 9.04 |
Ionis | 9.9B | -20.09 | 15.43 | -59.91% | -28.41% | 314.06 |
BridgeBio Pharma | 9.9B | -18.42 | -5.68 | 36.76% | 98.25% | -1.04 |
Moderna | 9.8B | 24.97 | 1.04 | -27.50% | -94.31% | 7.88 |
Financial data is updated regularly. All figures are in the company's reporting currency.